Navigation Links
Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
Date:3/20/2012

WELWYN GARDEN CITY, England and BOSTON, Massachusetts, March 20, 2012 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.

Under the terms of the agreement Heptares grants Shire an exclusive licence to worldwide development and commercial rights to A2Aantagonists discovered by Heptares. Heptares receives upfront option grant and exercise payments and is also eligible to receive future development and commercial milestone payments up to US$190 million plus royalties on product sales. Further terms of the agreement are not being disclosed.

Jeff Jonas, Senior Vice President, Research & Development, Specialty Pharmaceuticals and Regenerative Medicine, Shire, said:  "Shire is continuously in search of innovations that have the potential to help us develop well differentiated medicines that will bring value to patients. This agreement with Heptares is a reflection of our growth strategy of investing and focusing on highly targeted drug discovery platforms. We are impressed with the novelty and quality of the A2A antagonist leads generated by Heptares, resulting from what we believe to be the first time a structure-based drug discovery approach has been applied from the beginning to a GPCR drug target.  We look forward to a fruitful partnership with Heptares and to advancing the programme for the bene
'/>"/>

SOURCE Heptares Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oxygen Healthcare (O2h) Announces Expanded Chemistry Collaboration With Heptares Therapeutics
2. Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration With Oxygen Healthcare (O2h)
3. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
4. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
5. NSF CAREER grants support ocean energy, microforming, computer planning
6. Maryland Stem Cell Research Commission Announces New Program for Pre-Clinical and Clinical Research Grants
7. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
8. Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry
9. Cellectis bioresearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock
10. FDA Grants Fast Track Designation to Tioga Pharmaceuticals Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
11. FDA Grants Fast Track Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... (PRWEB) June 19, 2013 Bayer CropScience ... first Bayer Bee Care Community Leadership Award. The award ... Congressional Reception in Washington, D.C., an event where ... to the world’s food supply. , The Bayer ... harnessed the power of the honey bee colony to ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Adding ... Pipette.com is now stocked with Simport’s Dropette® and ... aimed at the customer doing basic biology, chemistry and ... and serology). , For over 35 years, Simport has ... plastic labware - products like the Simport Dropette®. Simport’s ...
Breaking Biology Technology:Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... (Nasdaq: MNKD ), focused on discovering, developing and,commercializing ... present at the UBS Global Life Sciences Conference on ... Hyatt Hotel in New York, NY. Interested parties ... of the,presentation in the Investor Relations section of the ...
... Sept. 18 InterMune, Inc.,(Nasdaq: ITMN ) today ... other conditions, 3,000,000 shares of its common stock in ... underwriters,a 30-day option to purchase up to an additional ... All of the shares in the offering,will be sold ...
... Sept. 18 /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today ... program,at the 43rd Scientific Sessions of the ... VIAject(TM) Phase II meal study data ... entitled, "Pharmacokinetics and pharmacodynamics of,insulin VIAject(TM), insulin ...
Cached Biology Technology:InterMune Announces Proposed Public Offering of Common Stock 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3
(Date:6/19/2013)... June 19, 2013 A decade-long JDRF-funded study ... Helmholtz Zentrum Mnchen, Germany, is providing a deeper ... risk of developing type 1 diabetes (T1D), highlighting ... for the disease. The study, "Seroconversion to Multiple ... in Children," was published today in The ...
(Date:6/19/2013)... , June 19, 2013  New York College ... the United States Patent and Trademark Office for detecting ... that reflect whether guards have been injured, attacked or ... extensive portfolio under the Intellectual Properties Agreements of New ... Pamintuan , President of New York ...
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical and ... the launch of a new open access journal, ... GeoResJ , Elsevier,s earth and planetary science journals portfolio ... aims to provide a forum for rapid publication of ... journal will be co-edited by six Executive Editors, each ...
Breaking Biology News(10 mins):New data on islet autoantibodies in young children defines early type 1 diabetes development 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
... a gene called p63 accelerates aging in mice. Similar versions ... Therefore, the p63 gene is likely to play a fundamental ... p63 gene works, we devised a system for eliminating it ... that these p63 deficient mice were aging prematurely," says Alea ...
... Genome Research Institute (NHGRI), one of the National Institutes ... Research Network will target 13 more organisms as part ... will expand biological knowledge and improve human health. , ... which is a federally chartered committee that advises NHGRI ...
... Skeletal muscles naturally repair themselves very efficiently after ... following damage from overuse during exercise, surgery or ... muscle repair slows noticeably, and in Duchenne Muscular ... functions can't cope with disease progression. , Researchers ...
Cached Biology News:Gene loss accelerates aging 2Possible treatment found for 'chemobrain' 2Possible treatment found for 'chemobrain' 3Possible treatment found for 'chemobrain' 4Possible treatment found for 'chemobrain' 5Muscle repair: Making a good system better, faster; implications for aging, disease 2Muscle repair: Making a good system better, faster; implications for aging, disease 3Muscle repair: Making a good system better, faster; implications for aging, disease 4
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Rice microRNA Microarray ...
... FP-6500 is the research-grade spectrofluorometer with a ... sensitivity S/N ratio 200 or greater for ... is especially designed to keep in mind ... as kinetics, stopped-flow, titration, or anisotropic measurements. ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
... designed for genome-wide microRNA expression profiling ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive microRNA Expression Profiling ... The Viruses microRNA Microarray contains all ...
Biology Products: